Recent Company News

• 07:01 AM ET Dec 26, 2025
  

  Can-Fite granted Brazilian patent for treatment of sexual dysfunction ($0.18, 0.00)

• 12:07 PM ET Dec 24, 2025
  

  Can-Fite BioPharma downgraded to hold from buy at D. Boral Capital ($0.17, -0.07)

• 04:49 PM ET Dec 23, 2025
  

  Can-Fite BioPharma announces 1-for-3,000 reverse split of ordinary shares; ADS ratio change ($0.24, 0.00)

• 09:22 AM ET Dec 16, 2025
  

  Can-Fite provides update on clinical development activities and financial status ($0.27, 0.00)

• 07:04 AM ET Nov 26, 2025
  

  Can-Fite BioPharma to present at Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference ($0.34, 0.00)

• 07:05 AM ET Nov 20, 2025
  

  Can-Fite receives notice of patent allowance in Brazil for CF602 erectile dysfunction treatment ($0.33, 0.00)

• 07:09 AM ET Nov 18, 2025
  

  Can-Fite BioPharma reports nine-year survival with complete cure in advanced liver cancer patient treated with Namodenoson ($0.36, 0.00)

• 06:15 AM ET Nov 04, 2025
  

  Can-Fite BioPharma assumed buy at HC Wainwright ($0.41, 0.00)

• 07:10 AM ET Sep 15, 2025
  

  Can-Fite provides update on cirrhosis patient treated with namodenoson ($0.66, 0.00)

• 08:51 AM ET Aug 28, 2025
  

  Can-Fite BioPharma reports H1 net income $0.0M vs year-ago $0.0M ($0.66, 0.00)